DOCSLIB.ORG

Neuroendocrine Complications of Cancer Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuroendocrine Complications of Cancer Therapy 05_Schwartz_Neuroendocrine 27.01.2005 9:39 Uhr Seite 51 Chapter 5 51 Neuroendocrine Complications of Cancer Therapy Wing Leung · Susan R. Rose · Thomas E. Merchant Contents 5.3 Detection and Screening . 67 5.1 Pathophysiology . 52 5.3.1 Signs and Symptoms Prompting 5.1.1 Normal Hypothalamic–Pituitary Axis . 52 Immediate Evaluation . 67 5.1.1.1 Growth Hormone . 53 5.3.2 Surveillance of Asymptomatic Patients . 67 5.1.1.2 Gonadotropins . 53 5.3.3 GH Deficiency . 67 5.1.1.3 Thyroid-Stimulating 5.3.4 LH or FSH Deficiency . 67 Hormone . 54 5.3.5 Precocious Puberty . 68 5.1.1.4 Adrenocorticotropin . 54 5.3.6 TSH Deficiency . 69 5.1.1.5 Prolactin . 54 5.3.7 ACTH Deficiency . 69 5.1.2 Injury of the Hypothalamic–Pituitary Axis 5.3.8 Hyperprolactinemia . 70 in Patients with Cancer . 56 5.3.9 Diabetes Insipidus . 70 5.1.3 Contribution of Radiation 5.3.10 Osteopenia . 70 to Hypothalamic–Pituitary Axis Injury . 56 5.3.11 Hypothalamic Obesity . 70 5.2 Clinical Manifestations . 60 5.4 Management of Established Problems . 71 5.2.1 GH Deficiency . 60 5.4.1 GH Deficiency . 71 5.2.2 LH or FSH Deficiency . 60 5.4.2 LH or FSH Deficiency . 73 5.2.3 Precocious 5.4.3 Precocious Puberty . 74 or Rapid Tempo Puberty . 63 5.4.4 Hypothyroidism . 74 5.2.4 TSH Deficiency . 64 5.4.5 ACTH Deficiency . 75 5.2.5 ACTH Deficiency . 66 5.4.6 Hyperprolactinemia . 76 5.2.6 Hyperprolactinemia . 66 5.4.7 Diabetes Insipidus . 76 5.2.7 Diabetes Insipidus . 66 5.4.8 Osteopenia . 76 5.2.8 Osteopenia . 66 5.4.9 Hypothalamic Obesity . 77 5.2.9 Hypothalamic Obesity . 66 References . 77 05_Schwartz_Neuroendocrine 27.01.2005 9:39 Uhr Seite 52 52 Chapter 5 W. Leung · S. R. Rose · T. E. Merchant Table 5.1. Anterior pituitary hormones and major hypothalamic regulatory factors Pituitary hormone Hypothalamic factor Effect Growth hormone Growth hormone-releasing hormone + Somatostatin – Prolactin Dopamine – Luteinizing hormone Gonadotropin-releasing hormone + Follicle-stimulating hormone Gonadotropin-releasing hormone + Thyroid-stimulating hormone Thyrotropin-releasing hormone + Somatostatin – Adrenocorticotropin Corticotropin-releasing hormone + Vasopressin + Effects on the hypothalamus are either stimulatory (+) or inhibitory (–) 5.1 Pathophysiology 5.1.1 Normal Hypothalamic–Pituitary Axis The hypothalamic–pituitary axis (HPA) is the pri- mary interface between the nervous system and the endocrine system.The actions and interactions of the endocrine and nervous systems constitute the major regulatory mechanisms for virtually all physiologic functions. The hypothalamus has extensive neural communications with other brain regions and regu- lates brain functions, including temperature, ap- petite, thirst, sexual behavior, and fear. The hypothal- amus also contains two types of neurosecretory cells (Fig. 5.1): (1) neurohypophysial neurons, which transverse the hypothalamic–pituitary stalk and re- lease vasopressin and oxytocin from their nerve end- ings in the posterior pituitary, and (2) hypophys- iotropic neurons, which release hormones into the portal hypophysial vessels to regulate the secretion of tropic hormones from the anterior pituitary. The six anterior pituitary hormones and their major hypo- Figure 5.1 thalamic regulatory factors are listed in Table 5.1. Diagrammatic representation of the hypothalamic– pituitary axis 05_Schwartz_Neuroendocrine 27.01.2005 9:39 Uhr Seite 53 Neuroendocrine Complications of Cancer Therapy Chapter 5 53 5.1.1.1 Growth Hormone Growth hormone (GH) is a 191-amino acid polypep- tide synthesized and secreted by the somatotrophs in the anterior pituitary gland in response to the hypo- thalamus releasing hormones, primarily GH-releas- ing hormone (GHRH) and somatostatin. GHRH se- cretion is usually steady, whereas somatostatin secre- tion is interrupted intermittently. Somatostatin con- tributes to the synthesis of GH in the pituitary but, paradoxically, inhibits GH release [45]. When so- matostatin concentrations decrease, the tonic con- centration of GHRH causes the release of GH into the systemic circulation. Factors such as neuropeptide Y, leptin, galanin, and ghrelin may also regulate GH secretion. In healthy children and adults, GH secre- tion is pulsatile,particularly during sleep,with two to a six pulses per night [50]. In adolescents, additional pulses occur during the day, and the pulses have higher peaks than those seen in children and adults (Fig. 5.2a). Circulating serum GH stimulates the production of insulin-like growth factor I (IGF-I) in all tissues. IGF-I mediates GH effects on growth, bone mineral- ization, and body composition (decreased fat deposi- tion, increased muscle mass) [71]. IGF-I is bound to IGF-binding proteins such as IGFBP3 and is trans- ported in the blood. IGF-I and IGFBP3 concentra- b tions are stable during the day and each reflects the integrated concentration of secreted GH. Figure 5.2 a,b a Changes with pubertal status in the normal daily pattern of growth hormone (GH), luteinizing hormone 5.1.1.2 Gonadotropins (LH), thyroid stimulating hormone (TSH), and adreno- corticotropin (ACTH) and cortisol secretion. b Normal Luteinizing hormone (LH) and follicle stimulating changes in LH and FSH levels from infancy to adoles- hormone (FSH) are glycoproteins both stored in the cence same cells in the anterior pituitary. Their overall pat- terns of secretion vary according to the age and gen- der of the person. The pituitary gland produces and secretes LH and FSH in a pulsatile manner in re- dren. In men, LH stimulates testosterone production sponse to a concordant episodic release of gonado- in the Leydig cells of the testes; normal spermatogen- tropin-releasing hormone (GnRH) from the hypo- esis requires both LH and FSH. In women, FSH stim- thalamus (Fig. 5.2a). The hypothalamic stimulus is ulates the production of estrogen and LH stimulates actively inhibited between 6 months of age and the the production of progesterone in the ovary. The LH onset of puberty (Fig. 5.2b). This inhibition can be surge near the end of the follicular phase of the men- disturbed by tumor mass, cranial surgery, or irradia- strual cycle is necessary to stimulate ovulation. De- tion, thereby resulting in precocious puberty in chil- velopment of the ovarian follicles is largely under 05_Schwartz_Neuroendocrine 27.01.2005 9:39 Uhr Seite 54 54 Chapter 5 W. Leung · S. R. Rose · T. E. Merchant FSH control, and the secretion of estrogen from the throughout the day; it peaks before the person awak- follicle is dependent on both FSH and LH (see section ens in the morning (Fig. 5.2a), increases with stress, 5.2.2 for information on the normal development of and is inhibited by glucocorticoids. Because cortisol the gonads). secretion is regulated by ACTH,cortisol secretion has characteristics similar to the secretion of ACTH. In 5.1.1.3 Thyroid-Stimulating Hormone addition to the negative feedback of glucocorticoids, ACTH inhibits its own secretion (short loop feed- Thyrotropin, also known as thyroid-stimulating hor- back). mone (TSH), is a glycoprotein synthesized in the an- terior pituitary.The secretion of TSH is stimulated by 5.1.1.5 Prolactin thyrotropin (or TSH)-releasing hormone (TRH) and inhibited by somatostatin and dopamine, secreted Prolactin (PRL) is a 198-amino acid polypeptide hor- from the hypothalamus. In persons older than 12 mone synthesized and secreted from the lactotrophs months of age,the TSH concentration is low in the af- of the anterior pituitary.A precursor molecule is also ternoon, rises dramatically (surges) after 1900 hours, secreted and can constitute as much as 10 %–20% of and reaches its highest concentrations between 2200 the PRL immunoreactivity in the plasma of healthy and 0400 hours (Fig. 5.2a) [51]. Thus, at least one persons.Hypothalamic control of PRL secretion (pri- third of the trophic influence of TSH on the thyroid marily through dopamine release) is different from gland occurs at night. TRH is necessary for TSH that of the other pituitary hormones in that the synthesis,post-translational glycosylation,and secre- hypothalamus inhibits, rather than stimulates, secre- tion of a fully bioactive TSH molecule from the pitu- tion of PRL. Thus, elevated PRL levels can be a use- itary [48]. Altered TSH glycosylation, resulting in ful marker of hypothalamic disorders that leave the altered bioactivity, is seen in mixed hypothyroidism pituitary intact. (central hypothyroidism with mild TSH elevation [5–15 mU/l]) [23, 49]. 5.1.2 Injury of the Hypothalamic–Pituitary Axis TSH stimulates the thyroid gland to produce in Patients with Cancer thyroxine (T4) and triiodothyronine (T3). T4 and T3 circulate in the blood stream bound to thyroxine- The hypothalamic–pituitary axis (HPA) is vulnerable binding globulin and albumin; only small amounts to damage by certain tumors, surgical trauma, irradi- are free or unbound. Free T4 undergoes intracellular ation, and chemotherapy [11, 60]. A summary of deiodination to form free T3,which interacts with the common risk factors for HPA disorders that develop DNA in a cell’s nucleus to influence cellular mRNA after cancer treatment is presented in Table 5.2. Pa- and protein synthesis. Free T4 also provides negative tients with tumors in the area of the HPA (e.g. cran- feedback to the hypothalamus and pituitary to mod- iopharyngioma or hypothalamic/chiasmatic tumor) ulate the secretion of TRH and TSH. are at particular risk for neuroendocrinopathy [15, 33]. Many HPA injuries are attributable to damage 5.1.1.4 Adrenocorticotropin caused by radiation therapy (see section 5.1.1.3). However, the incidence of pre-RT neuroendocrino- Adrenocorticotropin (ACTH) is a 39-amino acid pep- pathies in pediatric patients with brain tumors is tide hormone processed in the corticotrophs from a high. For example, out of 68 pediatric patients in one large precursor molecule, pro-opiomelanocortin. In study [32], 45 (66%) showed evidence of neuro- healthy individuals, hypothalamic corticotrophin-re- endocrinopathy before RT,including 15 of 32 patients leasing hormone and vasopressin are released in with tumors in the posterior fossa not adjacent to the two or three synchronous pulses per hour synergisti- HPA.
Load more

Recommended publications
  • Female Tanner Stages (Sexual Maturity Rating)
    Strength of Recommendations Preventive Care Visits – 6 to 17 years Bold = Good Greig Health Record Update 2016 Italics = Fair Plain Text = consensus or Selected Guidelines and Resources – Page 3 inconclusive evidence The CRAFFT Screening Interview Begin: “I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your Screening for Major Depressive Disorder -USPSTF answers confidential.” Age 12 years to 18 years 7 to 11 yrs No Yes Part A During the past 12 months did you: Screen (when systems in place for diagnosis, treatment and Insufficient 1. Drink any alcohol (more than a few sips)? □ □ follow-up) evidence 2. Smoked any marijuana or hashish? □ □ Risk factors- parental depression, co-morbid mental health or chronic medical 3. Used anything else to get high? (“anything else” includes illegal conditions, having experienced a major negative life event drugs, over the counter and prescription drugs and things that you sniff or “huff”) □ □ Tools-Patient Health Questionnaire for Adolescent(PHQ9-A) Tools For clinic use only: Did the patient answer “yes” to any questions in Part A? &Beck Depression Inventory-Primary Care version (BDI-PC) perform less No □ Yes □ well Ask CAR question only, then stop. Ask all 6 CRAFFT questions Treatment-Pharmacotherapy – fluoxetine (a SSRI) is Part B Have you ever ridden in a CAR driven by someone □ □ efficacious but SSRIs have a risk of suicidality – consider only (including yourself) who was ‘‘high’’ or had been using if clinical monitoring is possible. Psychotherapy alone or alcohol or drugs? combined with pharmacotherapy can be efficacious.
    [Show full text]
  • Inside Front Cover October 7.Pmd
    Early Female Puberty: A Review of Research on Etiology and Implications Eileen Daniel and Linda F. Balog Abstract Though the age of menarche has not decreased signifi cantly over the past 40 years, on average, girls began The age of female puberty appears to have decreased in to develop breasts one to two years earlier during the same the United States and western countries as child health time frame. African American girls typically begin thelarche and nutrition have improved and obesity has become more by age 9 compared to age 10 for White girls, though prevalent. Also, environmental contaminants, particularly approximately 15% of African American girls and 5% of endocrine disruptors, may also play a role in lowering the age White girls begin breast budding between the ages of 7 and of puberty. Puberty at an early age increases the risk of stress, 8 (Slyper, 2006). Currently, around 50% of all girls in the poor school performance, teen pregnancy, eating disorders, U.S. have begun to develop breasts by age 10 and 14% by substance abuse, and a variety of health issues which may ages 8 and 9. appear later in life including breast cancer and heart disease. The typical age range for the onset of puberty is between Articles for this literature review were located using a 8 and 14 years in girls while early puberty occurs between 7 computerized search of the databases Health Reference and 9, and precocious puberty generally takes place before Center, Medline, PsycINFO, and ScienceDirect from 2000 the age of 6 or 7 (Carel & Leger, 2008).
    [Show full text]
  • Pubertal Timing and Breast Density in Young Women: a Prospective Cohort Study Lauren C
    Houghton et al. Breast Cancer Research (2019) 21:122 https://doi.org/10.1186/s13058-019-1209-x RESEARCH ARTICLE Open Access Pubertal timing and breast density in young women: a prospective cohort study Lauren C. Houghton1* , Seungyoun Jung2, Rebecca Troisi3, Erin S. LeBlanc4, Linda G. Snetselaar5, Nola M. Hylton6, Catherine Klifa7, Linda Van Horn8, Kenneth Paris9, John A. Shepherd10, Robert N. Hoover2 and Joanne F. Dorgan3 Abstract Background: Earlier age at onset of pubertal events and longer intervals between them (tempo) have been associated with increased breast cancer risk. It is unknown whether the timing and tempo of puberty are associated with adult breast density, which could mediate the increased risk. Methods: From 1988 to 1997, girls participating in the Dietary Intervention Study in Children (DISC) were clinically assessed annually between ages 8 and 17 years for Tanner stages of breast development (thelarche) and pubic hair (pubarche), and onset of menses (menarche) was self-reported. In 2006–2008, 182 participants then aged 25–29 years had their percent dense breast volume (%DBV) measured by magnetic resonance imaging. Multivariable, linear mixed-effects regression models adjusted for reproductive factors, demographics, and body size were used to evaluate associations of age and tempo of puberty events with %DBV. Results: The mean (standard deviation) and range of %DBV were 27.6 (20.5) and 0.2–86.1. Age at thelarche was negatively associated with %DBV (p trend = 0.04), while pubertal tempo between thelarche and menarche was positively associated with %DBV (p trend = 0.007). %DBV was 40% higher in women whose thelarche-to-menarche tempo was 2.9 years or longer (geometric mean (95%CI) = 21.8% (18.2–26.2%)) compared to women whose thelarche-to-menarche tempo was less than 1.6 years (geometric mean (95%CI) = 15.6% (13.9–17.5%)).
    [Show full text]
  • Precocious Puberty Dominique Long, MD Johns Hopkins University School of Medicine, Baltimore, MD
    Briefin Precocious Puberty Dominique Long, MD Johns Hopkins University School of Medicine, Baltimore, MD. AUTHOR DISCLOSURE Dr Long has disclosed Precocious puberty (PP) has traditionally been defined as pubertal changes fi no nancial relationships relevant to this occurring before age 8 years in girls and 9 years in boys. A secular trend toward article. This commentary does not contain fi a discussion of an unapproved/investigative earlier puberty has now been con rmed by recent studies in both the United use of a commercial product/device. States and Europe. Factors associated with earlier puberty include obesity, endocrine-disrupting chemicals (EDC), and intrauterine growth restriction. In 1997, a study by Herman-Giddens et al found that breast development was present in 15% of African American girls and 5% of white girls at age 7 years, which led to new guidelines published by the Lawson Wilkins Pediatric Endocrine Society (LWPES) proposing that breast development or pubic hair before age 7 years in white girls and age 6 years in African-American girls should be evaluated. More recently, Biro et al reported the onset of breast development at 8.8, 9.3, 9.7, and 9.7 years for African American, Hispanic, white non-Hispanic, and Asian study participants, respectively. The timing of menarche has not been shown to be advancing as quickly as other pubertal changes, with the average age between 12 and 12.5 years, similar to that reported in the 1970s. In boys, the Pediatric Research in Office Settings Network study recently found the mean age for onset of testicular enlargement, usually the first sign of gonadarche, is 10.14, 9.14, and 10.04 years in non-Hispanic white, African American, and Hispanic boys, respectively.
    [Show full text]
  • Neonatal Breast Hypertrophy
    & The ics ra tr pe a u i t i d c e s P Pediatrics & Therapeutics Donaire et al., Pediatr Ther 2016, 6:3 ISSN: 2161-0665 DOI: 10.4172/2161-0665.1000297 Case Report Open Access Neonatal Breast Hypertrophy: Revisited Alvaro Donaire, Juan Guillen and Benamanahalli Rajegowda* Department of Pediatrics, Lincoln Medical and Mental Health Center, USA *Corresponding author: Benamanahalli Rajegowda, Department of Pediatrics, Division of Neonatology, Lincoln Medical and Mental Health Center, 234 East 149th Street, Bronx, New York, 10451, USA, Tel: 718-579-5360; Fax: 718-579-4958; E-mail: [email protected] Received date: Jun 28, 2016, Accepted date: Jul 14, 2016, Published date: Jul 18, 2016 Copyright: © 2016 Donaire A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. Introduction Neonatal breast enlargement is a benign condition that may be seen during the first days of life in the neonatal period and it has been reported to occur in 65-90% of infants. Within few months after birth it usually involutes, and later regrows during puberty due to hormonal stimulation. Breast enlargement is uncommon, when it occurs is a benign physical finding [1]. Neonatal galactorrhea, commonly referred to as witch’s milk, is a cloudy discharge from the breasts that occurs when estrogen and progesterone levels decrease after delivery, enabling the secretion of prolactin and oxytocin from the neonate’s pituitary [2]. The “witch’s milk” resembles the maternal milk composition, the milk comes only when the breast are expressed.
    [Show full text]
  • Premature Thelarche: a Guide for Families
    Pediatric Endocrinology Fact Sheet Premature Thelarche: A Guide for Families What is premature thelarche? to slightly increased. Some doctors will also order a bone age x-ray, but it is rare for the bone age to be significantly advanced, as is seen in true Thelarche is a medical term referring to the appearance of breast de- precocious puberty. velopment in girls, which usually occurs after age 8 years and is ac- companied by other signs of puberty, including a growth spurt. Prema- For girls who start developing breasts between the ages of 6 and 8 ture thelarche describes girls who develop a small amount of breast years, premature thelarche may still be the correct diagnosis, but true tissue (typically 1” or less across), typically before the age of 3 years. precocious puberty is more likely. Careful monitoring to see if there are The breasts do not get larger and the girl does not have a growth spurt. changes in the amount of breast tissue over time, additional tests, and A girl who has started puberty will show an increase in the size of her treatment are more likely to be needed. breasts within 4 to 6 months, but a girl with premature thelarche can go a year or more with little or no change in the size of the breasts How is premature thelarche treated? (sometimes, they will get smaller). Usually, both breasts are enlarged, but, sometimes, premature thelarche only affects one side. Premature Because this condition does not progress and there are no compli- thelarche differs from true precocious puberty, in which the typical cations, no medications are necessary.
    [Show full text]
  • Predicting Pubertal Development by Infantile and Childhood Height, BMI, and Adiposity Rebound
    nature publishing group Clinical Investigation Articles Predicting pubertal development by infantile and childhood height, BMI, and adiposity rebound Alina German1, Michael Shmoish2 and Ze’ev Hochberg3 BACKGROUND: Despite substantial heritability in puber- in these late maturing children is U-shaped (6,7). During the tal development, children differ in maturational tempo. transition from childhood to juvenility, which usually occurs Hypotheses: (i) puberty and its duration are influenced by early when children are aged about 6 y, the BMI rebounds immedi- changes in height and adiposity. (ii) Adiposity rebound (AR) is a ately after it reaches its nadir—the so-called adiposity rebound marker for pubertal tempo. (AR) (8,9). A young age and a high BMI at the age of rebound METHODS: We utilized published prospective data from 659 predicts a high BMI in early adulthood, and it has been sug- girls and 706 boys of the Study of Early Child Care and Youth gested that the occurrence of a high BMI at 3 y of age leads to Development. We investigated the age of pubarche-thelarche- a rebound at a younger age (10). gonadarche -menarche as a function of early height, BMI, and Since height and BMI at certain critical ages can predict AR. the timing and duration of puberty, the working hypotheses RESULTS: In girls, height standard deviation scores correlated of this investigation are (i) the onset of puberty, menarche, negatively with thelarche and pubarche from 15 mo of age and pubertal progression and duration are influenced by early and with menarche from 54 mo. BMI correlated negatively changes in height and adiposity and (ii) the age of occurrence with thelarche from 36 mo of age and menarche from 54 mo.
    [Show full text]
  • Hormone Phenotypes and the Timing of Pubertal Milestones in a Longitudinal Cohort of Girls
    Hormone Phenotypes and the Timing of Pubertal Milestones in a Longitudinal Cohort of Girls Cecily Shimp Fassler [email protected] The University of Cincinnati College of Medicine Department of Environmental Health - Epidemiology November 7, 2019 https://www.menstrupedia.com/articles/puberty/physical-changes-girls Hormones During Puberty Hormone levels change throughout puberty.1 1. Gonadotropin-releasing hormone (GnRH) is released at the beginning of puberty. 2. The follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are then released into the bloodstream. 3. LH and FSH stimulate the ovaries to produce estrogen (estradiol, estrone, and estriol) to initiate breast development. 4. The adrenal gland hormones, DHEA-S (dehydroepiandrosterone sulfate) and testosterone, stimulate pubic hair growth. 2 1 Peper JS, Dahl DE. Surging hormones: brain behavior interactions during puberty. Curr Dir Psychol Sci. 2013 April;22(2): 134-139. 2 Braude, P, Hamilton D. Hormone changes during puberty, pregnancy, and menopause. Obstetric and Gyneocologic Dermatology 2008;3:3-12. https://abdominalkey.com/normal-puberty-and-pubertal-disorders/ Hormones Attributes Mean hormone values across time related to thelarche (time=0)* 20 15 10 5 0 -18 -12 -6 Thelarche (0) 6 Estradiol (pg/mL) Estrone (pg/mL) Testosterone (ng/dL) * Note the units of each hormones differ. Individual Girl’s Hormones Objective Determine if the hormone levels in girls around the time of thelarche are the same for all girls or if girls have different patterns in increases and decreases in hormone levels. • Identify peri-pubertal hormone phenotypes (or clusters) in young girls based on hormone levels around thelarche (e.g. estradiol at -6 and 0 or testosterone and estrone at 0).
    [Show full text]
  • Premature Thelarche: a Possible Adrenal Disorder
    Arch Dis Child: first published as 10.1136/adc.57.3.200 on 1 March 1982. Downloaded from Archives of Disease in Childhood, 1982, 57, 200-203 Premature thelarche: a possible adrenal disorder MIRO DUMI(, MELITA TAJIH, DUSKO MARDEWIC, AND ZRNKA KALAFATIC Paediatric Clinic, Medical Faculty, University ofZagreb, Yugoslavia SUMMARY Endocrine studies in girls with precocious thelarche were compared with those of normal girls of similar ages. Girls with precocious thelarche showed breast development and oestrogenised vaginal smears as the only signs of precocious sexual development. A few of the girls were tall and some had advanced bone ages but these two findings were not consistently present in the same patient. Hormones-such as serum oestradiol, oestrone, A 4-androstenedione, progesterone, dehydroepiandrosterone (DHEA), follicle-stimulating hormone, luteinising hormone, and prolactin, and urinary 17-ketosteroids-were measured. Only DHEA was different, being higher in girls with precocious thelarche. It is suggested that the high DHEA level may serve as a precursor for conversion to oestrogens in the target tissues, breast, and vagina. This mechanism for oestrogenisa- tion has been reported in other patients. Premature thelarche is the term that Wilkins applied matographed as described by Judd and Yen.15 to describe precocious breast development in young Radioimmunoassay of all steroids was performed any Biolab kits. Variation girls who do not manifest other sign of pubertal with (Limal, Belgium) copyright. development.1 Although premature thelarche is coefficients of plasma duplicate determination of common in young girls, there have been few recent oestradiol, oestrone, and progesterone were 9, 7, and reports of the disorder.2-'3 The aetiology is unclear.
    [Show full text]
  • Delayed Menarche: What Does It Look Like? What to Do?
    Delayed menarche: what does it look like? what to do? Melina Dendrinos, MD Michigan Medicine Primary Care for Women Conference 12/5/19 Disclosures • No significant financial interests or other relationships with industry relative to topics that will be discussed. Objectives • After this lecture the learner will be able to 1. Review normal pubertal development 2. Recognize delayed menarche and create a differential diagnosis. 3. Describe a plan for initial evaluation of delayed menarche. Puberty • Complex sequence of biological events resulting in • Maturation of secondary sex characteristics • Breast development (thelarche) • Pubic and axillary hair development (adrenarche) • Accelerated linear growth • Attainment of reproductive capacity Emans and Laufer, 2012 Onset of puberty • Mechanism of initiation of puberty is poorly understood • Inhibitory, stimulatory, and nutrition-dependent factors act on hypothalamus • Gradual changes in amplitude and frequency of GnRH pulses from the hypothalamus. • Timing of initiation is dependent on • Genetics • Health and nutrition Emans and Laufer, 2012 Changes in GnRH pulsatility • Prepubertal • Early pubertal • Late pubertal Oxford Textbook of Endocrinology and Diabetes, 2011 Hypothalamic-pituitary-ovarian axis • GnRH causes secretion of gonadotropins • Ovarian stimulation • Maturation of germinal epithelium • Synthesis of hormones • LH acts on theca cells • Produce androgen precursors • FSH acts on granulosa cells • Produce aromatase to convert precursors to estradiol Emans and Laufer, 2012 Effects
    [Show full text]
  • Breast-Infants
    n Breast Enlargement in Infants (Premature Thelarche) n What are some possible Premature thelarche is a condition in which the breasts of baby girls begin to enlarge. It is usually complications of premature a temporary, harmless condition. Breast enlarge- thelarche? ment in infants and young girls is sometimes the Usually none. The condition often goes away on its own, first sign of early (precocious) puberty, but this is although this may take a few years. uncommon. Infrequently, premature thelarche is the first sign of early (precocious) puberty. This is most likely when the breasts start to enlarge after ages 2 to 3, accompanied by other What is premature thelarche? signs of puberty such as an enlarged clitoris or develop- ment of pubic hair. Treatment may be needed to halt the Premature thelarche is enlargement of the breasts in infant process of early maturation. girls. Most often, breast enlargement is the only abnormality. It is occasionally the first sign of early (precocious) puberty. This is more likely if the breasts become enlarged after ages What puts your child at risk 2to3. of premature thelarche? Usually there is no apparent cause of early breast enlarge- There are no known risk factors. ment, although it can result from exposure to medications or to sources of the hormone estrogen. The breasts may remain enlarged for as long as a few years but eventually go down Can premature thelarche in size before your daughter starts puberty. be prevented? There is no way to prevent this condition. What does it look like? How is premature thelarche ’ Your daughter s breasts start getting bigger.
    [Show full text]
  • Breastfeeding and Timing of Pubertal Onset in Girls: a Multiethnic Population-Based Prospective Cohort Study Sara Aghaee1, Julianna Deardorff2, Louise C
    Aghaee et al. BMC Pediatrics (2019) 19:277 https://doi.org/10.1186/s12887-019-1661-x RESEARCHARTICLE Open Access Breastfeeding and timing of pubertal onset in girls: a multiethnic population-based prospective cohort study Sara Aghaee1, Julianna Deardorff2, Louise C. Greenspan3, Charles P. Quesenberry Jr.1, Lawrence H. Kushi1 and Ai Kubo1* Abstract Background: Early puberty is associated with higher risk of adverse health and behavioral outcomes throughout adolescence and adulthood. US girls are experiencing earlier puberty with substantial racial/ethnic differences. We examined the association between breastfeeding and pubertal timing to identify modifiable risk factors of early puberty and potential sources of racial/ethnic differences in the timing of pubertal development. Methods: A prospective cohort study of 3331 racially/ethnically diverse girls born at Kaiser Permanente Northern California (KPNC) between 2004 and 06. All data were obtained from KPNC electronic clinical and administrative datasets. Mother-reported duration of breastfeeding was obtained from questionnaires administered at each ‘well- baby’ check-up exam throughout the baby’s first year and categorized as ‘Not breastfed’, ‘Breastfed < 6 months’, and ‘Breastfed ≥ 6 months’. Pubertal development data used Tanner stages assessed by pediatricians during routine pediatric checkups starting at age 6. Pubertal onset was defined as transition from Tanner Stage 1 to Tanner Stage 2+ for breast (thelarche) and pubic hair (pubarche). Weibull regression models accommodating for left, right, and interval censoring were used in all analyses. Models were adjusted for maternal age, education, race/ethnicity, parity and prepubertal body mass index (BMI). We also examined race/ethnicity as a potential effect modifier of these associations.
    [Show full text]